Sevelamer Hydrochloride Tablet, Film Coated
Product Images NDC 33342-242

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sevelamer Hydrochloride (NDC 33342-242). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

400mg-360s (Sevelamer Bottle 400mg 360s)

Label for Sevelamer Hydrochloride Tablets 400 mg, film-coated oral tablets. The label includes the Macleods Pharma USA branding, the NDC 33342-241-65, and states 360 tablets per container. It details storage instructions, dosage referral to prescribing information, and manufacturer details including Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd., India.*

FDA Label Image

800mg-180s (Sevelamer Bottle 800mg 180s)

Label for Sevelamer Hydrochloride Tablets 800 mg film-coated oral tablets, packaged as 180 tablets. The label includes manufacturer information: Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd., India. It provides storage instructions and notes to dispense in a tight container and protect from moisture, with temperature storage guidelines between 20° to 25°C.*

FDA Label Image

800mg-30s (Sevelamer Bottle 800mg 30s)

Label for Sevelamer Hydrochloride Tablets 800 mg, film-coated oral tablets, with a count of 30 tablets. The label shows that it is manufactured for Macleods Pharma USA, Inc. and by Macleods Pharmaceuticals Ltd., India. Storage instructions and dosage guidance referencing prescribing information are also visible.*

FDA Label Image

Figure-2 (Sevelamer Figure 2)

A line graph comparing Sevelamer Hydrochloride and an active control, showing the percentage of patients with at least a certain reduction versus the reduction in serum phosphorus (mg/dL). The graph's x-axis ranges from -4 to 8 mg/dL, indicating worsened increase to improved reduction, while the y-axis shows the percentage of patients from 0 to 100%.*

FDA Label Image

Figure-3 (Sevelamer Figure 3)

Line graph showing phosphorus change from baseline over 52 study weeks. Two treatment groups are compared: Sevelamer Hydrochloride (black circles) and Active-Control (red squares). The y-axis represents phosphorus change, ranging from -5 to 2, and the x-axis shows study weeks from 0 to 52. The Sevelamer Hydrochloride group shows a greater decrease in phosphorus levels over the study period compared to the Active-Control group.*

FDA Label Image

Figure-1 (Sevelamer Structure)

Chemical structure diagram of sevelamer hydrochloride, showing its polymeric repeating units with amine and hydrochloride groups, including hydroxyl-substituted components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.